Literature DB >> 11901098

Regioselective metabolism of taxoids by human CYP3A4 and 2C8: structure-activity relationship.

Thierry Cresteil1, Bernard Monsarrat, Joelle Dubois, Michelle Sonnier, Paul Alvinerie, Françoise Gueritte.   

Abstract

Paclitaxel and docetaxel are metabolized by liver microsomal monooxygenases into inactive metabolites further eliminated from the body via the bile route. In spite of their close chemical structure, the two drugs are oxidized by two different enzymes; CYP2C8 catalyzes the 6-hydroxylation on the taxane ring of paclitaxel, whereas CYP3A4 oxidizes docetaxel on the tert-butyl group of the lateral chain in C13. Since paclitaxel and docetaxel differ only by two substitutions, the role of individual modifications was investigated; the regioselectivity of hydroxylation was assessed by high-pressure liquid chromatography/mass spectrometry, and enzymes implicated in individual reactions were identified using human liver microsomes and recombinant P450 expressed in Ad293 cells. The biotransformation of docetaxel, 10-deacetylpaclitaxel, and 10-deacetylbaccatin III was steadily increased (2- to 5-fold) by the addition of an acetyl group in position 10, suggesting that the presence of a hydrophobic group in position 10 stimulated hydroxylation by P450 proteins. The absence of the lateral chain at C13 in baccatin III severely impaired the metabolism supported by CYP3A4. The presence of a tert-butyl group in the lateral chain of docetaxel favored the hydroxylation on the tert-butyl by CYP3A4, whereas the presence of a phenyl group in the lateral chain facilitated the oxidation on the taxane ring by CYP2C8. Collectively, these data strongly suggested that the structure of the lateral chain and the nature of substituent in position 10 play an important role in determining the regioselective oxidation by P450 proteins and modulate the reaction rate by human liver microsomes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11901098     DOI: 10.1124/dmd.30.4.438

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  15 in total

1.  Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver.

Authors:  Shu-Yun Zhang; Sailesh Surapureddi; Sherry Coulter; Stephen S Ferguson; Joyce A Goldstein
Journal:  Mol Pharmacol       Date:  2012-06-20       Impact factor: 4.436

Review 2.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

Review 3.  Clinical Pharmacokinetics of Paclitaxel Monotherapy: An Updated Literature Review.

Authors:  Tore B Stage; Troels K Bergmann; Deanna L Kroetz
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

Review 4.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Taxane pathway.

Authors:  Connie Oshiro; Sharon Marsh; Howard McLeod; Michelle Whirl Carrillo; Teri Klein; Russ Altman
Journal:  Pharmacogenet Genomics       Date:  2009-12       Impact factor: 2.089

Review 6.  Pharmacogenetics of Breast Cancer Treatments: A Sub-Saharan Africa Perspective.

Authors:  Keneuoe Cecilia Nthontho; Andrew Khulekani Ndlovu; Kirthana Sharma; Ishmael Kasvosve; Daniel Louis Hertz; Giacomo Maria Paganotti
Journal:  Pharmgenomics Pers Med       Date:  2022-06-21

7.  The algal hepatoxoxin okadaic acid is a substrate for human cytochromes CYP3A4 and CYP3A5.

Authors:  Fujiang Guo; Tianying An; Kathleen S Rein
Journal:  Toxicon       Date:  2009-08-20       Impact factor: 3.033

Review 8.  PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8.

Authors:  Christina L Aquilante; Mikko Niemi; Li Gong; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-12       Impact factor: 2.089

Review 9.  Pharmacogenomics of breast cancer therapy: an update.

Authors:  Kelly Westbrook; Vered Stearns
Journal:  Pharmacol Ther       Date:  2013-03-13       Impact factor: 12.310

10.  Actionable pharmacogenetic markers for prediction and prognosis in breast cancer.

Authors:  Keith Sacco; Godfrey Grech
Journal:  EPMA J       Date:  2015-07-22       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.